Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274219 · ClinicalTrials.gov registry record · Phase 1
Study of bb21217 in Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by 2seventy bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 11
- Study locations
NCT03274219: Completed Phase 1 study of Multiple Myeloma, sponsored by 2seventy bio.
NCT03274219 is a Phase 1 study of Multiple Myeloma that has completed, run by 2seventy bio. The registered enrollment target is 72 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03274219, a Phase 1 study of Multiple Myeloma, has completed, sponsored by 2seventy bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
Conditions Studied
Interventions
- BIOLOGICAL bb21217
Study Locations (11)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- UCSF Medical Center at Parnassus - San Francisco
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Insitute, Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Minnesota
- Mayo Clinic Cancer Center - Rochester
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
New York
- Mount Sinai Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03274219
The ClinicalTrials.gov registry entry for NCT03274219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is 2seventy bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which bb21217 is the first listed.
NCT03274219 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03274219 about?
NCT03274219 is a clinical study titled "Study of bb21217 in Multiple Myeloma". Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT03274219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2017-08-16. Estimated completion is 2022-12-02.
What conditions does trial NCT03274219 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03274219?
The interventions under investigation include: bb21217 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03274219?
This trial is sponsored by 2seventy bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03274219 being conducted?
This trial has 11 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.